Renal pathology features in arterial hypertension patients with and without metabolic syndrome
Abstract
The study included 303 patients (110 men, 193 women) with Stage I-III arterial hypertension (AH), aged 25–70 years (mean age 52±18 years). All participants were divided into two groups, comparable by age and sex distribution: Group A (n=151) – with metabolic syndrome (MS), and Group B (n=152) – without MS. Each group was divided into three subgroups, according to AH stage (I, II, III). All patients underwent clinical examination, 24-hout blood pressure (BP) monitoring, renal function assessment (glomerular filtration rate, GFR, and microalbuminuria, MAU). MS criteria were specified according to the recommendations by International Diabetic Foundation (IDF, 2005). The data obtained demonstrated that MAU was an early marker of renal pathology in AH, especially when combined with MS. MAU level was significantly higher in individuals with AH and MS, comparing to hypertensive participants without metabolic disturbances. Group A demonstrated significant correlations between MAU, lipid and carbohydrate metabolism parameters and circadian BP profile. GFR correlation with MS was substantially weaker.
About the Authors
G. Kh. Sharipova
Институт клинической кардиологии им.А.Л.Мясникова, РКНПК Росмедтехнологий, Москва
Russian Federation
Russian Federation
I. E. Chazova
Институт клинической кардиологии им.А.Л.Мясникова, РКНПК Росмедтехнологий, Москва
Russian Federation
Russian Federation
References
1. Арутюнов Г.П., Чернявская Т.К., Лукичева Т.И. и др. Микроальбуминурия и пути ее медикаментозной коррекции // Клин. фармакол. и тер.- 1999.-№ 3.-С. 23–28.
2. Диагностика и лечение метаболического синдрома. Рекомендации ВНОК. Москва 2007 г.
3. Дедов И. И., Шестакова М.В.. Максимова М.А., Федеральная целевая программа «Cахарный диабет». 2002; Москва, Методические рекомендaции.
4. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза, Москва 2005 г.
5. Моисеев В.С., Мухин Н.А., Кобалава Ж.Д. и др. Основные положения проекта рекомен-даций Всероссийского научного общества нефрологов России по оценке функционального состояния почек у больных сердечно-сосудистыми заболеваниями или с повышенным риском их развития// Кардиоваскулярная терапия и профилактика; № 4,2008, 8–20.
6. Преображенский Д. В., Маревич А. В., Романова И. Е. и др. Микроальбуминурия: диагностическое, клиническое и прогностическое значение (часть вторая)// Росс. Кардиол. ж. 2000; 4: 78–85.
7. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (второй пересмотр). Москва.2004 г.
8. Andronico G, Ferraro-Mortellaro R, Mangano M.T et al. Insulin resistance and glomerular hemodynamics in essential hypertension// Kidney Int, 2002.Sep; 62(3);1005–9.
9. Bonnet F, Marre M, Halimi J.M et al. Waist circumference and the metabolic syndrome predict the development of elevated almuminuria in non-diabetic subjects: the DESIR Study// J Hypertension; 2006; 24(6) 1157–1163.
10. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine// Nefron 1976;16:31–41.
11. Chang Y, Yoo T, Ryu S et al. Abdominal obesity, systolic bood pressure and MAU in normotensive and euglicemic Korean men//Int. Obes (lond); 2006; 30 (5) 800–804.
12. Cbagnac A., Weinstein T, Korzets A, et al. Glomerular hemodinamics in severe obesity//Am J Renal Physio 2000; 278; F817-F822.
13. Cirillo M., Senigalliesi L., Laurenzi M. et al. Microalbuminuria in nondiabetic adults; relations of blood pressure, body mass index, plasma cholesterol levels and smoking The GUBBIO Popylation Study// Arch. Intern. Med. 1998; 158 (17): 1933–1939.
14. Mule G, Nardi E, Cottone S. еt al. Influence of metabolic syndrome on hypertensionelated target organ damage//J Intern Med. 2005; Jun: 257;(6);503–513.
15. O’Brien E., Sheridan R., O’ Malley K et al. Dippers and non-dippers (letter)//Lancet 1988: 2: 397–398.
16. Okpechi I.G, Pascoe M.D, Swanepoel C.R et al. MAU and the metabolic syndrome in non Diabetic black Africans//Diab Vasc Dis Res. 2007 Dec;4;(4);365–367.
17. Pontremoli R., Nicolella С., Viazzi F. et al. Microalbuminuria is an early marker of target organ damage in essential hypertension// Am. J. Hypertens. 1998; 11 (4): 430–438.
18. Palaniappan L., Carnethon M., Fortmann S.P., Association between MAU and the metabolic syndrome: NHANES III// Am.J Hypertens 2003: 16:952–958.
19. The Heart Outcomes Prevention Evaluation study Investigators. Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients// N. Engl. J. Med. 2000; 342: 145–153.
20. Verdeccia P. Prognostic value of ambulatory blood pressure. Current evidence and Clinical implications // Hypertension, 2000; 35; 844–851.
21. Wolf G., Chen S. Han D.C et al. Leptin and renal disease // Am J Kidney Dis. 2002; 39: 1– 11.
Review
For citations:
Sharipova G.Kh., Chazova I.E. Renal pathology features in arterial hypertension patients with and without metabolic syndrome. Russian Journal of Cardiology. 2008;(6):4-9. (In Russ.)
Views:
463
Email this article 